October 07, 2016
RealTime Dynamix™: Crohn’s Disease US Q3 2016 Spotlight
RealTime Dynamix™: Crohn’s Disease Q3
Gastroenterologists poised to adopt Janssen’s recently approved Stelara
(ustekinumab) for the treatment of Crohn’s disease
RealTime Dynamix™: Crohn’s Disease Q3 is the first installment of a quarterly publication focusing on current and anticipated trends in the Crohn’s disease (CD) market. Analysis covers the major inline brands including Remicade, Humira, Entyvio, Cimzia, Simponi, and Tysabri, as well as key pipeline agents, including Stelara and Xeljanz.
Gastroenterologists Report a Substantial Need for New Agents for the Treatment of Crohn’s Disease, Can Stelara Fill it?
Under one quarter of IBD patients
are not achieving optimal results on
current biologic
“There is a strong need for
additional biologic options for the
treatment of IBD”
“The addition of IL-12/23 inhibitors
as IBD treatment options will greatly
improve my ability to efficiently
treat IBD”
On the Eve of the FDA Approval, 1 in 5 US Gastroenterologists Report Off-Label Use of the IL12/23 Inhibiting, Stelara in CD
Off-Label Stelera Users
Additionally, when asked about changes made to the treatment and management of CD patients in the past six months…
6% report (unaided) that they have begun using Stelara for the treatment of their CD patients.
Existing Familiarity with Stelara Should Bolster Early Uptake in CD
Gastroenterologist Familiarity With Agents In Development
Stelara is indicated for CD patients who have failed/intolerant to corticosteroids, immunomodulators or TNF-inhibitors
one-third plan to use the biologic after two or more biologic failures.
Likely Position of Stelara in the CD Treatment Algorithm If Approved
In RealTime Dynamix: Crohn’s Disease Q4 We will focus on the initial experience of Stelara in
practice and the impact on biologic market dynamics and sequencing